Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Bioservo

Related articles:
1/5/2024 5:55:18 AM - Bioservo avnoteras från First North med sista handelsdag 11 januari - Teknikbolaget Bioservo kommer kliva av börsen och avnoteras den 11 januari efter att Nasdaq godkänt ansökan. Det framgår av ett pressmeddelande.
12/30/2023 4:10:34 PM - Hilbert årets vinnare och Quiapeg årets förlorare på First North 2023 - Marknadsplatsen Nasdaq First North Growth Market i Stockholm består av drygt 400 bolag och här blandas bolag av alla storleksklasser. Det innebär att stora kursrörelser åt bägge hållen inte är något ovanligt.
12/15/2023 9:43:53 AM - Bioservo ansöker om avnotering från First North inför likvidation - Teknikbolaget Bioservo beslutade på extra bolagsstämma den 14 december att bolaget ska träda i frivillig likvidation. Styrelsen har därför lämnat in en ansökan om avnotering av bolagets aktie från First North. Sista handelsdag kommer meddelas när börsen har gett besked. Det framgår av ett pressmeddelande.
11/27/2023 9:25:52 AM - Bioservo: Proposed liquidation - Redeye - Redeye comments on the news that Bioservo has initiated the process of liquidation.
11/8/2023 6:14:27 AM - Bioservo: High activity level - Redeye - Redeye saw sales that were in line with our expectations. The positive Carbonhand development helped sales to recover from the weak previous quarter. The cost-cutting is having an effect, and even slightly faster than expected. Carbonhand in Europe has a positive momentum, and we expect that there will be orders from the US soon. The report, in line with our lowered expectations, makes us make some small changes.
11/7/2023 7:43:30 AM - Bioservo Q3’23: Sales traction in the Quarter - Redeye - Redeye saw sales that were in line with our expectations. The Carbonhand sales have now started to appear more meaningfully, and there has been some positive news around the progress in some European countries. Cost continued to trend lower, as expected, and came in better than expected in the quarter. We are optimistic about the potential and possibilities as we advance. Sales development is on the slow side, while the market signals are improving. We expect to lower our Fair value range and Base case as the sales development in the short perspective is uncertain, and there is a financing need approaching if sales do not increase as expected at the beginning of 2024e. Based on the predicted estimate changes, our Base case will be tentatively lowered by 20%.
10/19/2023 8:13:29 AM - Bioservo Technologies: Better momentum in Germany - Redeye - Redeye comments on the better-indicated momentum for Carbonhand in Germany.
10/12/2023 7:23:06 AM - Bioservo: Weighing options - Redeye - Redeye comments on today’s news that Bioservo is exploring alternatives to accelerate commercialization by appointing a committee to look into different strategic options.
8/21/2023 5:34:35 AM - Bioservo Q2’23: Soft top-line development - Redeye - Redeye saw sales that were considerably lower than our expectations. The Ironhand sales did not take off as expected in the quarter. Cost is starting to trend lower, as expected. Short-term sales uncertainty overshadows the positive development surrounding Carbonhand in Europe and the US. Given the sales deviation from our estimates, we lower our expectations for the second half of 2023e. With these changes, we reduce our Fair value range to SEK 0.7 (1.2) and 5.6 (6.7), respectively, and our Base case to SEK 2.4 (3.3) per share. The long-term positive view on the potential and possibilities are relatively unchanged with strong interest, especially surrounding Carbonhand.
8/18/2023 7:00:16 AM - Bioservo Q2’23: Sales not reaching expectations - Redeye - Redeye saw sales that were considerably lower than our expectations. The Ironhand sales did not take off as expected in the quarter. Cost is starting to trend lower, as expected. Short-term sales uncertainty overshadows the positive development surrounding Carbonhand in Europe and the US. We will reduce our sales estimates due to the deviation in Q2 and for the H2 of 2023e, as while we are optimistic about the potential and possibilities as we advance, sales development is on the slow side. We expect to lower our Fair value range and Base case as the uncertainty of the progress of the sales in the short perspective is significant. Based on the predicted estimate changes, our Base case will be tentatively lowered to between SEK 2.3 to 2.6 (3.3) per share.
8/16/2023 6:52:44 AM - Bioservo: Progress in the US sales structure - Redeye - Redeye comments on the wholesale distributor agreement in the US with VHSS. Bioservo is working on setting up the structure in the US, where we see this kind of agreement as a first step to getting a foothold in the quite substantial Veterans Healthcare market. The deal with Veterans Healthcare Supply Solutions (VHSS) based in Jacksonville, FL, is a positive step in our view and shows the growing interest in the Carbonhand solution in the US. Bioservo is due to publish its Q2 report on Friday, 18 August.
6/13/2023 7:47:58 AM - Bioservo: Redeye resumes coverage following rights issue - Redeye - Redeye resumes its coverage of Bioservo Technologies following the completion of the rights issue, adding SEK 37m before transaction cost.
5/15/2023 7:04:17 AM - Bioservo: Rights Issue Announced – We Pause Our Coverage - Redeye - Redeye gives a short comment on the announced rights issue and pauses its coverage.
4/25/2023 8:05:18 AM - Bioservo: Commercialization progress - Redeye - Redeye saw results that did not represent a significant deviation from the expectations. The sales were up 58%, with costs trending downward. The deliveries of Carbonhand have started, and interest looks pretty high from different stakeholders. The earlier-than-expected US progress with the FDA registration is a clear positive. We only change our estimates slightly: however, the financing need adds another share issue of SEK 30 m, creating a dilution effect. We lower our Base case to SEK 3.3 per share from SEK 5 per share.
4/25/2023 7:21:39 AM - Bioservo Q1’23: Good start to 2023 on several fronts - Redeye - Redeye saw sales roughly in line with our expectations in the Q1 report, as deliveries of Carbonhand were made in the quarter. The costs was starting to trend lower as per the cost-cutting program. The fact that Carbonhand is now registered as a 510(k) by FDA opens up for sales in the US earlier than expected.
4/24/2023 7:16:44 AM - Bioservo: US FDA 510(k) approval for Carbonhand - Redeye - Redeye is positive that Bioservo has registered Carbonhand as a medical-technical product according to the 510(k) exemption. This progress has come earlier than expected and means that Bioservo can now start marketing Carbonhand in the US, and work to set up the partner structure can be initiated. This is a milestone for the company as the US market has the most significant potential for these products. Sales in the US will realistically commence in 2024e, and Bioservo will now work to get the appropriate reimbursement codes in place (Healthcare Procedure Coding System). Bioservo is tomorrow publishing its Q1’23 report before the market opens.
3/17/2023 11:15:40 AM - Bioservo: Getting a grip on the Australian market - Redeye - Redeye is viewing the progress in bringing Carbonhand to the market as encouraging. After regulatory approval and is listed as a medical device, the latest approval for sales in Australia is another step to get sales going as a whole.
2/22/2023 9:10:59 AM - Bioservo: Prepped for commercialization going into 2023 - Redeye - Redeye saw no breakthrough in sales in Q4, and costs were higher than expected. During Q4, there has been some positive development. The financial situation has improved with the share issue, Carbonhand has been MDR approved, and the iHand study was very positive. Cost reductions have been implemented that will come into effect during 2023e. We both lower and increase our estimates and change the number of shares. The estimate changes and some balance sheet maintenance alter our Base Case to SEK 5 (6) per share. We still see a compelling long-term case, and the Carbonhand commercialization has the potential to surprise.
2/22/2023 8:06:52 AM - Bioservo: Q4’22, Initial take – Focus on 2023 - Redeye - Redeye saw sales lower than our expectations in the Q4 report partly due to the delays for Carbonhand in the quarter. The cost was also higher as the company has increased its cost to push for the commercialization of Carbonhand going into 2023e. The final results of the iHand study and the MDR are strong points going into 2023.
2/15/2023 8:35:23 AM - Bioservo: Positive outcome of Waupaca trials - Redeye - Redeye is encouraged by the positive results at the Waupaca Foundry, where both the employees are satisfied, and incident reports show incident rates substantially lower. The positive trial has now rendered that Waupaca rolls out the Ironhand system at three additional sites, thus bringing the total number of Ironhand in use in these facilities to 60 systems. The value of the supplemental order is SEK 1.8m. Bioservo is reporting its Q4 numbers next week.
1/25/2023 9:12:00 AM - Bioservo: Good start for Carbonhand - Redeye - Redeye comments on the first deliveries of the new Carbonhand to patients and is happy to see a good start for the Carbonhand launch.
11/15/2022 8:26:15 AM - Bioservo Q3’22: Breakthrough at the horizon - Redeye - Redeye reduces our short-term lower estimated number of systems to be sold during 2022e and, to an extent, in 2023e. The estimate changes lower our Base Case to SEK 6 (8) per share, partly also due to a higher risk-free rate in our model. We still see a compelling long-term case; however, with the financing sorted, the pathway to commercialization is more straightforward.
11/11/2022 8:26:22 AM - Bioservo: Getting a grip on the market - Redeye - Redeye is pleased that Bioservo’s Carbonhand 2.0 has now been classified and approved as a medical device according to the MDR, thus opening up for sales in Europe.
10/11/2022 7:50:23 AM - Bioservo: Carbonhand strong out of the gate - Redeye - Redeye comments on the strong initial news flow around the launch of the new Carbonhand. The agreement with an Australian distributor is encouraging and shows the strong offering from Bioservo in this segment. It is also positive that the distributor started by putting in an initial order, although small, thus an excellent start to the cooperation.
9/14/2022 10:59:34 AM - Bioservo: Launch of next generation Carbonhand - Redeye - Redeye is positive regarding the news that Bioservo is now launching the long-awaited next generation of Carbonhand.
8/31/2022 7:24:50 AM - Bioservo Q2’22: Inflection point delayed - Redeye - Redeye reduces our short-to mid-term estimates due to a lower estimated number of systems to be sold during 2023E and, to an extent, into 2024E. The estimate changes and new issues alter our Base Case to SEK 8 per share. We still see a compelling long-term case; however, the commercialization of Ironhand has taken longer than we expected.
8/12/2022 10:01:21 AM - Bioservo: Moving along with the commercialization of Carbonhand - Redeye - Redeye has a positive view of the new distribution agreement for Carbonhand in Switzerland. This is a good step into a well-functioning market for prescribing assistive devices and is a good step in the commercialization process for the new Carbonhand version.
6/9/2022 1:32:53 PM - Bioservo: Positive preliminary results in iHand study - Redeye - Redeye has a positive view of the preliminary results from the ongoing iHand study presented at the IFSSH & IFSHT in London.
5/4/2022 8:24:32 AM - Bioservo: Edging closer to the inflection point - Redeye - Redeye adjusts the short-term estimates downward due to a slightly more challenging business environment. The changes in estimates negatively affect our fair value range; however, we are still optimistic about the long-term prospects of both Ironhand and Carbonhand. We lower our Base case to SEK 16 (18) per share.
5/3/2022 7:05:16 AM - Bioservo Q1’22: First take - Redeye - Redeye's first impressions on the Q1 report from Bioservo earlier this morning. The sales although small, were slightly better than expected. On the other hand, the cost levels were also higher, partly due to the cost of a non-recurring nature of an extensive commercial analysis for Carbonhand. Apart from this, the report does not show any significant surprises.
2/18/2022 9:00:05 AM - Bioservo Q4’21: Interesting Runway for Growth - Redeye - Redeye comments on the Q4 report from Bioservo. In total, a report without any surprises in our view. Sales are still low as expected, and costs are maintained at reasonable levels. We are making minor adjustments to our estimates as we roll over our DCF model. We reiterate our fair value range of SEK 10 to 28 per share with a Base case of SEK 18 per share.
2/17/2022 8:37:32 AM - Bioservo Q4’21: Initial Take - Redeye - Redeye's first impressions on the Q4 report from Bioservo earlier this morning. We see a report that is devoid of any significant surprises. As expected, the sales numbers are still small, while Covid still hampers sales efforts. The total operating income and EBIT are marginally below our expectations.
11/9/2021 12:59:35 PM - Bioservo Q3’21: Positive signals of an awakening Market - Redeye - Redeye comments on the Q3 report from Bioservo, where we see improving growth and lower cost levels. We are making minor adjustments to our estimates based on the costs and higher other operating income in the quarter. We reiterate our fair value range of SEK 10 to 28 per share with a Base case of SEK 18 per share.
9/29/2021 7:12:24 AM - Bioservo: Adding growth capital - Redeye - Redeye comments on last night's direct share issue.
9/7/2021 8:04:58 AM - Bioservo: Inflection point getting closer - Redeye - Redeye initiates coverage of Bioservo Technologies, a Swedish technology, and medical technology company. Bioservo develops and produces soft exoskeletons for industrial and Life Science use. We see an attractive case with significant upside potential. We now see that the company is approaching an inflection point for long-term growth.
2/26/2021 9:20:12 AM - Bioservo: Utvärdering hos GM pågår - Analysguiden - Vi fortsätter se stor potential i Bioservos produkterbjudande.
12/10/2020 6:59:37 AM - Erik Pensers mäklarchef lyfter fram Ossdsign och Bioservo - Di - Erik Pensers mäklarchef Oskar Ekman lyfter fram Ossdsign och Bioservo som intressanta bolag som kan bli börsraketer. Det rapporterar Dagens industri.
8/26/2020 9:35:34 AM - Bioservo: Hög försäljningstillväxt i utmanande tider - Analysguiden - Bioservo visar upp ett starkt utfall för årets andra kvartal med en försäljningstillväxt på 37 procent. Siffrorna domineras helt av leveranser till den franska maskinuthyraren Loxam. Inför årets andra hälft ser orderboken svagare ut men bolaget kommer i höst visa upp sina produkter på viktiga mässor i Europa.